Saturday, October 31, 2015

Weekend Reading AASLD 2015 Key Abstracts and Treatment of HCV Genotype 3: Where are we now?

Weekend Reading AASLD 2015 Key Abstracts and Treatment of HCV Genotype 3: Where are we now?

Ready for Halloween? Around here the excitement builds, however once again the weather might not cooperate.  It may be a busy time around your house as well, but if you find yourself here in search of HCV information, I hope you consider it time well spent.

We start with a few headlines followed by key AASLD 2015 HCV Abstracts to be presented at the upcoming meeting, and last but not least the latest issue of Clinical Liver Disease.

In The News

Up to 4800 patients potentially exposed to hepatitis C at Ogden ...
OGDEN — Up to 4,800 people may have been exposed to hepatitis C by a now-fired nurse at McKay-Dee Hospital between June 2013 and November 2014, ...

CDC: Small portion of hepatitis C outbreaks occur in hospitals
Standard-Examiner - ‎9 hours ago‎
In the past eight years, 22 cases of healthcare-related hepatitis C were reported to the Centers for Disease Control and Prevention, according to the CDC's report detailing cases from 2008-2014.

Findings about WWII-Era Spread of Hepatitis C Could Inform Future Prevention Efforts
The breakneck pace of clinical research means that, by necessity, there is little time to assess the past. But research published earlier this year in the Journal of Virology on the origins of the Hepatitis C virus (HCV) shows that such examination is not a morbid trip down memory lane, but rather can deliver key insights into current prevention efforts

Yet another stunning victory in the drug battle against the liver-damaging hepatitis C virus (HCV) may be in the offing: A small study suggests it may be possible to cure some people of their infections in as few as 3 weeks.

Tattoos drawing attention
The Dunedin City Council has been working with police and the Hepatitis C Resource Centre Otago to try to combat the problem, but hepatitis C health promoter Allison Beck said they were fighting an uphill battle.
''Anecdotally, yes I can say we have seen an increase in hepatitis C traced back to unsafe backyard tattooing jobs,'' she said.

CATOOSA — The Cherokee Nation is getting some help to address the rate of hepatitis C in northeastern Oklahoma.

Merck CEO Says Drug-Price Debate Doesn't Account for R&D Risks
Merck will probably introduce its own hepatitis C treatment next year. “If you didn't have a system that created an incentive for people like AbbVie or Merck to ...

There are 160m carriers of the hepatitis C virus across the world. Combined with the hepatitis B virus, which has 240m carriers, this causes 1.4m deaths every year.

Gilead Submits NDA to U.S. FDA for Fixed-Dose Combination of Sofosbuvir/Velpatasvir for Treatment of All Six Genotypes of Hepatitis C
-- If Approved, Combination Would Be First All-Oral, Pan-Genotypic Single-Tablet Regimen for Chronic HCV Infection --

 Pharmacy benefit manager Express Scripts Holding Co said the potential risk of liver injury from AbbVie' hepatitis C treatments has not impacted the availability of the treatment for patients for whom it is safe and effective.

Statins Seem to Reduce Efficacy of Flu Vaccines
By Joe Elia
Edited by Susan Sadoughi, MD, and Richard Saitz, MD, MPH, FACP, FASAM
Two studies suggest that statins may lower the efficacy of flu vaccines, although commentators call the results "hypothesis generating" and not a reason to...

The flu vaccine is provided free by the NHS to those living with serious health conditions as part of the NHS’s ‘Stay Well this Winter’ campaign. For most healthy people, flu is an unpleasant but usually self-limiting disease with recovery taking up to a week. People with flu are approximately 11 times more likely to die if they have an underlying health condition than if they don’t.

  An update has suggested that all patients, with the exception of patients with short life expectancies not related to HCV, should be treated with newer HCV medications.
Medscape Medical News, October 29, 2015 

The most recent issue of the Journal of Viral Hepatitis conducted a meta-analysis to investigate the association between HCV infection and preterm birth.

Special Issue: Managing Patients With Liver Disease
A special issue of Clinical Gastroenterology and Hepatology is dedicated to the clinical management of hepatic disorders, including nonalcoholic fatty liver disease (NAFLD), viral hepatitis, autoimmune hepatitis, and primary sclerosing cholangitis (PSC). The issue comprises 14 review articles that aim to present clinicians with evidence-based guidance and expert opinions on management of patients with liver

Hepatitis C Research Blog
Key AASLD 2015 HCV Abstracts: Dr. Lebovics
Posted on October 30, 2015
Hepatology, Creighton University, Phoenix, AZ

Click here for an overview of key HCV abstracts recommended by Dr. Lebovics to be presented at the upcoming liver meeting, including Gilead and Abbvie regimens.

Clinical Liver Disease© The American Association for the Study of Liver Diseases
Clinical Liver Disease (CLD) is the latest online learning resource of The American Association for the Study of Liver Diseases (AASLD.) CLD blends text, audio, video, webinars, and other interactive content into educational interventions launched every two months. These interventions are designed for any physician or healthcare provider caring for a patient with liver disease.

Special Issue: New Treatments for CLD, Ethics and Liver Disease, Liver Transplantation & Non-Cirrhotic Portal Hypertension

New Treatments for CLD
Guest Edited by Nancy Reau, MD
Treatment of patients with hepatitis C virus genotype 3: Where are we now? (pages 79–81)
Carmen Landaverde, Jennifer T. Wells, Julio Gutierrez and Fred Poordad
Article first published online: 28 OCT 2015 | DOI: 10.1002/cld.506

Management of patients with hepatitis C virus resistance–associated variants to NS5A inhibitors: Where are we now? (pages 82–85)
Jennifer T. Wells, Carmen Landaverde, Julio Gutierrez and Eric Lawitz
Article first published online: 28 OCT 2015 | DOI: 10.1002/cld.507

Ethics and Liver Disease
Guest Edited by Andrew Aronsohn, MD
What Is the ethical (Not Legal) responsibility of a physician to treat minimal hepatic encephalopathy and advise patients not to drive? (pages 86–89)
Mette M. Lauridsen, James B. Wade and Jasmohan S. Bajaj
Article first published online: 28 OCT 2015 | DOI: 10.1002/cld.501

Transplant tourism versus proper travel for transplantation (pages 90–91)
John S. Gill and Francis L. Delmonico
Article first published online: 28 OCT 2015 | DOI: 10.1002/cld.503

What Is the moral responsibility of health care providers to report HBV or HCV status if they perform invasive procedures? (pages 92–95)
Jessica L. Mellinger
Article first published online: 28 OCT 2015 | DOI: 10.1002/cld.504

Liver Transplantation
Guest Edited by Paul Martin ' Kalyan Ram Bhamidimarri

Bone disease in cirrhosis (pages 96–99)
Nishita Patel and Santiago J. Muñoz
Article first published online: 28 OCT 2015 | DOI: 10.1002/cld.498

Criteria for liver transplantation in hepatocellular carcinoma (pages 100–102)
Laura Kulik
Article first published online: 28 OCT 2015 | DOI: 10.1002/cld.499

Non-Cirrhotic Portal Hypertension
Guest Edited by Theo Heller, MD, Ohad Etzion, MD, and Christopher Koh, MD

Systemic disease associated with noncirrhotic portal hypertension (pages 103–106)
David Semela
Article first published online: 28 OCT 2015 | DOI: 10.1002/cld.505
This too is can be a "HUGE" undertaking, although emerging data from clinical trials is promising, real world data, or HCV cure rates in real-life patients is lacking. So lets start with a few links with proven outcomes.

Just For Fun

Enjoy Halloween!

No comments:

Post a Comment